Navigation Links
Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress
Date:11/8/2010

nical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of the economy on our business; our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; our success retaining current contracts or levels of reimbursement coverage for our tests; the risks and uncertainties associated with the regulation of our tests by FDA; the impact of healthcare legislation on our business; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.Genomic Health, Inc.Condensed Consolidated Statements of Operations (in thousands, except share and per share data)For the Three Months Ended For the
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., ... therapeutics, including those with rare and orphan inflammatory disease ... the U.S. Food and Drug Administration (FDA) to begin ... candidate, acebilustat (CTX-4430), in adult CF patients in the ... Europe will be filed soon ...
(Date:7/6/2015)... FRANCISCO, Calif. , July 6, 2015 ... pharmaceutical company, and Oculeve, a development-stage medical device company ... today announced that they have entered into an agreement ... transaction.  Under the terms of the agreement, Allergan will ... commercialization milestone payments related to Oculeve,s lead development program ...
(Date:7/6/2015)... , July 6, 2015 China Information Technology, Inc. ... provider of integrated cloud-based platform, exchange, and big data ... that the Company launched its mobile app for Healthcare ... healthcare services on mobile devices. The Company jointly hosted ... Family Planning Bureau and Shenzhen News Net.   ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... Naviscan, Inc., the worldwide leader in 3D Molecular ... PhD has joined the Naviscan Board of Directors. ... related to reimbursement in the medical device industry.  He ... Reimbursement at Acclarent, Inc.  After acquisition by Ethicon, Inc., ...
... Calif., July 14, 2011 Molecular Devices, LLC, ... & development, life science research, and bioassay/test development, ... Accreditation (A2LA) has accredited the Laboratory Quality System ... re-calibration processes. (Logo: http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ...
Cached Medicine Technology:Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng 2Molecular Devices Continues to Lead the Way in Quality Control and Validation Compliance With a New ISO/IEC 17025 Accreditation 2
(Date:7/4/2015)... York, NY (PRWEB) , ... July 04, 2015 , ... When a hacker gains access ... home front and at the office. On Wednesday, July 1st, the FTC issued a ... credentials as part of a verification process for a password reset instigated by the hacker. ...
(Date:7/3/2015)... ... July 03, 2015 , ... On June 30th ... new SEO training system called "Page One Engine" . The program, which ... received glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national president recruitment for Regional Care, ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients ... existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, the ... , offering timely lawsuit updates and ovarian cancer warning information. The site is routinely ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer ... week that he says will reveal biblical truth and expose popular lies regarding proper ... Bible Say Don’t Have Sex”, immediately goes into the core of the subject by ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... VA, Washington DC, FREDERICKSBURG, Va., Oct. 28 ... 500 percent increase in the number of,patients seeking ... age spots, sun damage, melasma (brown skin patches),acne ... The doctors suggest that increased demand for ...
... ATLANTA, Oct. 28 As October, Breast Cancer ... Blue Shield of Georgia (BCBSGa),understands that it is ... to further improve breast cancer care and awareness ... designed for patients with breast,cancer and their physicians, ...
... from Orrick, Herrington & Sutcliffe Law Firm to Present ... Better ... Experiences, SANTA CLARA, Calif., Oct. 28 Agito ... today,announced that one of its enterprise fixed mobile convergence ...
... Tianyin,Pharmaceutical, Co., Inc., (Amex: TPI ), a ... based in Chengdu, China,today announced that the Company,s ... repurchase program., On October 27, 2008, the ... to $3.0 million of its common stock through ...
... Catalyst,Biosciences, Inc., a pioneer in the discovery ... has appointed Todd Lorenz,M.D., as the company,s Chief ... of experience focused on the clinical,development of novel ... Lorenz to the Catalyst team," said,Nassim Usman, Ph.D., ...
... costs and medical crises fuel many foreclosures, bankruptcies , , ... Deborah Krinsky of Magalia, Calif., have seen their health ... their health-care costs have put them in a financial ... potential heart problems, Deborah,s connective tissue disorder and fallen ...
Cached Medicine News:Health News:Fraxel(R) Laser at Plastic Surgery Services of Fredericksburg Proves Popular Treatment in Cost-Conscious Economy 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 2Health News:Blue Cross and Blue Shield of Georgia Expands Breast Cancer Care Program 3Health News:Agito Networks Customer Selected to Present at the Mobile Enterprise Executive Summit 2008 Conference 2Health News:Agito Networks Customer Selected to Present at the Mobile Enterprise Executive Summit 2008 Conference 3Health News:Agito Networks Customer Selected to Present at the Mobile Enterprise Executive Summit 2008 Conference 4Health News:Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program 3Health News:Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer 2Health News:Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer 3Health News:Medical Debt Sending Many Over Financial Brink 2Health News:Medical Debt Sending Many Over Financial Brink 3
... 700 Series is an advanced three-part inflatable prosthesis ... a pump placed in the scrotum and a ... It closely simulates the look and performance of ... penile implant technology, the AMS 700 Series now ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
Medicine Products: